Effects of dapagliflozin on renal function in type 1 diabetes patients in the real world: A retrospective multicenter study of the KAMOGAWA-A cohort
Authors' conclusion
At 24 months, the decline in eGFR was significantly lower in the dapagliflozin group than in the non-use group without increasing diabetic ketoacidosis and hypoglycemia.
Study context
- Population
- T1D patients, KAMOGAWA-A cohort; median estimated glomerular filtration rate (eGFR) 74.0 mL/min/1.73 m²255 analysed
- Participants
- 295 patients
- Exposure
- Dapagliflozin vs non-use
- Dapagliflozinn = 76
- Non-usen = 179reference
- Outcome
- Change in eGFR
- Follow-up
- 24 months
Methodological detailsmulticenter, 1:1 propensity score matching, linear mixed model
- Multicenter
- 1:1 propensity score matching
- Linear mixed model
Main finding
As reported in the abstract
Least squares mean change in eGFR
Dapagliflozin
−3.14
least squares mean · 95% CI −5.62–-0.66 · mL/min/1.73 m²
Non-use
−6.94
least squares mean · 95% CI −9.39–-4.50 · mL/min/1.73 m²
P = 0.032
Observational data: associations, not effects.
Secondary outcomes
Change in HbA1c, total insulin dose and urinary albumin-to-creatinine ratio (UACR) · 24 months
- HbA1c, total insulin dose and UACR change significantly lower with dapagliflozin than non-use
Original publication
Effects of dapagliflozin on renal function in type 1 diabetes patients in the real world: A retrospective multicenter study of the KAMOGAWA-A cohort. Diabetes Res Clin Pract. Published 17 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →